Multicomponent Prehabilitation and Outcomes in Elderly Patients With Frailty
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jan 15, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special program called prehabilitation can help older patients with frailty who are having surgery for digestive cancer. Prehabilitation involves activities like exercise, nutrition support, and education to prepare patients for surgery and improve their recovery. The goal is to see if this approach can lead to better health outcomes both right after surgery and in the long term.
To participate in the study, you need to be at least 65 years old and no older than 89, and scheduled for major surgery lasting two hours or more for digestive cancer. You also need to have a certain level of frailty, which means you may have some difficulties with daily activities. However, if you have certain medical conditions or cannot take part in rehabilitation for other reasons, you may not be eligible. If you join, you can expect to engage in activities that will help you prepare for your surgery, with the hope of improving your recovery and overall well-being.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Age ≥65 years but \<90 years;
- • 2. Scheduled to undergo major surgery for digestive cancer with an expected duration of 2 hours and longer, including cancers of esophagus, stomach, small intestine, colon, rectum, pancreas, liver, and biliary tract;
- • 3. Clinical Frailty Scale ≥5;
- • 4. Provide written informed consent.
- Exclusion Criteria:
- • 1. Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis;
- • 2. Inability to communicate due to coma, profound dementia, or language barrier;
- • 3. Inability to participate in preoperative rehabilitation due to paralysis, fracture or other movement disorder;
- • 4. Inability to take oral diet due to preoperative gastrointestinal disease or other disease;
- • 5. Severe heart dysfunction (left ventricular ejection fraction \<30% or New York Heart Association classification IV), severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (undergoing dialysis before surgery), or American Society of Anesthesiologists classification of grade 4 or higher;
- • 6. Other reasons that are considered unsuitable for study participation.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Dong-Xin Wang, MD, PhD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials